BTAI
BioXcel Therapeutics, Inc.
NASDAQ · Healthcare · Biotechnology · US
$0.07
+64.22%Year over year
Reported trailing growth
- Revenue
- -14.5%
- EBITDA
- -54.3%
- EBIT
- +13.7%
- EPS
- +56.9%
- Free cash flow
- —
- Operating cash flow
- —
Forward estimates
Based on analyst estimates
- Revenue
- —
- EBITDA
- —
- EPS
- —
Three-year CAGR
- Revenue
- +19.6%
- EBITDA
- -19.1%
- EBIT
- +25.2%
- Net income
- -17.3%
- EPS
- +75.6%
- Free cash flow
- +20.0%
Reported trailing growth, forward expectations and three-year compound growth rates · Data as of Jun 1, 2026